Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Product Development

Pfizer dips into translational regulation for cancer with eFFECTOR deal

Pfizer’s deal with eFFECTOR points to translational regulators as an emerging target source

January 9, 2020 1:03 PM UTC
Updated on Feb 25, 2020 at 9:45 PM UTC

eFFECTOR’s deal with Pfizer is the latest indication that translational control elements are a promising, emerging source of new drug targets. The companies teamed up to develop small molecule inhibitors of the translation initiation complex subunit eIF4E to treat cancer.

eFFECTOR Therapeutics Inc. will receive $15 million up front and up to $429 million in R&D funding and development and sales milestones through the licensing and collaboration agreement...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article